an un - buffered solution of amide anesthetic can remain stable for years , but once it is buffered to make it more bio - active , the solution will remain stable for only a few days before it loses solubility , precipitates , and becomes useless . to mitigate the problem of insolubility following buffering high concentration anesthetics , the invention provides two components , an aqueous solution of anesthetic at low ph , and a buffering solution comprising preferably a mixed phosphate base . the invention stores the anesthetic component and the buffer component separately , which allows maximizing the buffer ph independently of the anesthetic concentration . mixing a high (& gt ; 8 ) ph buffer solution with a high (& gt ; 2 %) concentration anesthetic solution produces a high (& gt ; 1 %) concentration aqueous solution of topical anesthetic having a ph around 7 . this combination verges on instability : a small increase in ph would cause the active ingredient to become insoluble and to precipitate immediately , thereby dramatically reducing the bio - availability of the active ingredient . to obtain a margin of solubility , preferably a mixed phosphate base ( potassium dihydrogen orthophosphate and dipotassium hydrogen orthophosphate ) buffering solution having a ph of 8 is used for the buffering component . sodium hydroxide may also be a suitable buffering component . a & gt ; 2 % concentration of ph 3 . 8 lidocaine is preferably used for the anesthetic component , although other amide anesthetics may also be suitable . the ph and viscosity levels are set to reflect the target organ . anesthetic buffering component component mixture ph 2 . 5 - 5 7 - 11 5 . 5 - 7 concentration & gt ; 2 % 0 & gt ; 1 % of anesthetic to delay coalescence and postpone precipitation of the ingredient molecules within the mixture of the two solutions , the two solutions are rapidly mixed together in a special technique called “ speed mixing .” anesthetic compound molecules in a solution naturally tend to combine , crystallize , and precipitate as larger solids which can no longer penetrate through tissue to a target . a solubilizing agent ( or “ enhancer ”) in a solution inhibits crystallization , and thereby increases the solubility , of chemicals ( e . g ., anesthetic agents ) in the solution . this enables the solution to hold a higher concentration of the anesthetic agent and thereby increases the bio - availability , potency , and effect of the anesthetic agent . since anesthetic concentration is not lost , it does not need to begin at a higher than optimum level . the invention in an embodiment having lignocaine as the active ingredient and having a phosphate based buffer preferably incorporates into the buffer n - methyl - 2 - pyrrolidone as an enhancer . afterwards , upon mixing the buffer and the anesthetic , any small quantities of drug that begin to crystallize are immediately solubilised and forestalled from acting as seed sites for precipitation . topical anesthetics need to be applied directly to their site of action . doing this may be relatively simple when the target tissue is visible to the physician and accessible without the need to pass body openings . however when the target tissue is within a body cavity , a major barrier is presented by the cumulative mass of secretions , tissue debris , blood , exudates , etc . in order to displace this mass , the viscosity of the anesthetic vehicle must be higher than that of blood and exudates , and high enough to help the solution adhere to uterine walls . a benefit of having a viscosity slightly higher than that of blood is that capillary force attracts the vehicle containing the anesthetic molecules to remain within the bodily cavity for the time needed for the anesthetic molecules to transfer from the liquid vehicle into the target tissue . on the other hand the viscosity must not be much higher than that of blood , to preserve the solution &# 39 ; s ability to flow easily and enter intended - to - be - anesthetized nooks and crannies of the bodily cavity that are inaccessible to more viscous gels . viscous aqueous x - ray solutions are known to spread to nooks and crannies of uterine cavities and into tubes , and to remain there for hours . to obtain a suitable viscosity , the invention preferably adds hydroxypropyl methylcellulose in 50 : 50 proportions to both components . various concentrations were tested to find a level that provided a good balance of properties stable at the natural and buffered ph . a concentration of 0 . 1 % was found to provide a suitable viscosity . this agent effectively maintains the viscosity of the aqueous solution , and is generally unaffected by ph in the range of 3 to 11 . sonography has shown the invention , with a similar level of viscosity in an embodiment identified as hystagel ™, penetrating and being retained in uterine cavities for several hours after instillation . mixing is postponed until just prior to the procedure , and then done up to a number of hours prior to use . mixing these anesthetic and buffering components in a 1 : 1 ratio produces a & gt ; 1 % concentration aqueous solution having a ph of around 7 . this delivers the product with good bio - availability and effectiveness . once mixed , the anesthetic is stable for several hours , and in terms of efficacy , ease of use , application and persistence it is very effective as a local anesthetic . while the present invention is described in terms of a preferred embodiment , it will be appreciated by those skilled in the art that this embodiment may be modified without departing from the essence of the invention . it is therefore intended that the following claims be interpreted as covering any modifications falling within the true spirit and scope of the invention .
for use in bodily cavities , a topical anesthetic combination having a ph adjusted to optimize the effectiveness of the anesthetic , a viscosity appropriate to displace tissue debris and enhance retention , and addition of chemicals which increase the bio - availability of the anesthetic molecules .